To amend title 18, United States Code, to prohibit former employees of covered health agencies from serving on the board of entities involved in development and research of a drug, biological product, or device and from profiting from a drug, biological product, or device, and for other purposes.
About This Bill
Committee
Latest Action · May 1, 2024
Read twice and referred to the Committee on the Judiciary.
The FAUCI Act would impose new restrictions on senior federal health officials from the National Institutes of Health, Food and Drug Administration, and Centers for Disease Control and Prevention. The bill prohibits these top officials from serving on the boards of companies that develop or research drugs, biological products, or devices for eight years after leaving their government position, and bars them from profiting from such products if they were involved in approving related grant applications during their employment. Violations of the board service prohibition would carry penalties under existing law, while profiting from approved drugs or devices could result in fines up to $250,000 and imprisonment for one to five years. The bill also prevents current top officials from obtaining patents for drugs, biological products, or devices and requires existing officials and their spouses to disclose any patent ownership within 180 days of the law's enactment. The restrictions would apply to individuals leaving federal service after the bill's enactment, with a six-month compliance period for those who left before enactment.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.